%0 Case Reports
%T Neuromyotonia with Central Nervous System Lesions following Quadrivalent Human Papilloma Virus Vaccination.
%A Hatami M
%A Förster M
%A Weyers V
%A Räuber S
%A Meuth SG
%A Kremer D
%A Hatami M
%A Förster M
%A Weyers V
%A Räuber S
%A Meuth SG
%A Kremer D
%J Vaccines (Basel)
%V 10
%N 7
%D Jul 2022 16
%M 35891296
%F 4.961
%R 10.3390/vaccines10071132
%X Neuromyotonia is a rare peripheral nerve hyperexcitability syndrome often associated with antibodies directed against contactin-associated protein-like 2 and leucine-rich, glioma inactivated 1. The quadrivalent human papilloma virus vaccine Gardasil®, first approved in 2006, is known to be a highly effective prophylaxis against papillomavirus types 6, 11, 16, and 18. Molecularly, this non-infectious recombinant vaccine is based on purified L1 proteins from the human papilloma virus capsid. Since the approval of this vaccine, several studies have investigated its safety regarding the occurrence of autoimmune conditions following application. Here, we present the first case of neuromyotonia with active Gadolinium enhancing demyelinating central nervous system lesions following vaccination with Gardasil®.